196170 - Alteogen Inc.

196170 Summary

Biopharma

Stock Price & Overview

₩288,500 +5,500 (+1.94%) Close · Sep 4, 2026 KST

KOSDAQ | ₩KRW | Close: ₩288,500 ≈ US$206 · Market cap ₩20.1tn (≈ $14.4bn)

196170 Financial Statements

Breakdown ₩ bn	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015
Total Revenue	215.9	102.9	96.5	28.8	38.7	42.4	29.2	13.7	12.1	6.8	4.7
Cost of Revenue	50.2	38.8	65.3	24.3	33.0	23.7	18.1	11.7	11.1	6.2	1.3
Gross Profit	165.6	64.1	31.2	4.5	5.8	18.8	11.1	2.0	1.0	0.6	3.5
Selling, General & Administrative	58.7	38.7	40.9	33.9	21.0	18.8	13.4	9.6	7.2	6.0	3.3
Operating Income	106.9	25.4	-9.7	-29.4	-15.2	-0.1	-2.3	-7.7	-6.2	-5.4	0.1
Finance Income	56.4	7.9	5.3	3.9	2.1	0.9	0.9	0.8	0.5	0.6	0.6
Finance Costs	12.3	4.1	0.7	0.4	0.6	0.8	0.2	0.0	0.0	0.0	0.0
Pretax Income	162.7	36.6	-3.6	-10.0	-10.7	-17.7	-1.7	-6.0	-7.4	-4.5	1.0
Income Tax Expense	17.6	-24.1	0.0	0.1	0.9	0.6	-0.1	1.0	0.1	-0.9	-0.2
Net Income	145.2	60.7	-3.6	-10.1	-11.6	-18.3	-1.7	-7.1	-7.4	-3.6	1.2
Total Comprehensive Income	145.2	60.7	-3.6	-10.1	-11.6	-18.3	-1.7	-7.1	-7.4	-3.6	1.2

Breakdown ₩ bn	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015
Total Assets	698.7	409.0	256.1	245.5	258.3	159.2	86.0	71.4	43.0	47.9	39.4
Current Assets	480.8	211.8	144.1	145.1	210.2	137.9	65.2	58.3	35.7	39.3	26.7
Cash & Cash Equivalents	66.4	19.0	30.2	45.8	10.5	38.9	4.4	8.9	5.2	8.4	7.1
Inventories	6.5	1.0	1.1	1.6	1.0	0.5	0.9	0.5	0.2	0.2	0.0
Trade Receivables	29.6	20.2	16.7	8.8	4.3	2.7	1.8	4.6	1.5	1.7	0.4
Non-current Assets	217.9	197.2	112.0	100.4	48.1	21.3	20.8	13.1	7.3	8.6	12.7
Property, Plant & Equipment	40.4	19.2	18.8	27.0	29.3	19.3	19.2	11.7	5.0	4.7	4.1
Intangible Assets	120.1	112.1	89.3	47.2	11.2	0.9	0.6	0.5	0.5	2.1	0.2
Total Liabilities	244.3	134.9	108.3	100.1	126.8	98.6	15.8	4.7	3.2	2.7	0.8
Current Liabilities	239.7	129.2	100.4	94.3	122.8	97.0	11.4	2.5	2.7	2.2	0.4
Non-current Liabilities	4.6	5.7	7.8	5.8	4.0	1.6	4.4	2.2	0.5	0.5	0.4
Total Equity	454.4	274.1	147.8	145.4	131.5	60.6	70.2	66.7	39.8	45.2	38.6
Share Capital	26.8	26.7	26.5	26.2	21.5	14.0	6.9	6.9	6.3	3.1	3.0
Retained Earnings	218.5	76.9	14.6	18.0	-35.3	-29.1	-13.2	-12.5	-5.7	1.8	5.4

Breakdown ₩ bn	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015
Cash from Operating Activities	124.1	53.0	-7.8	-17.9	-9.5	1.5	9.1	-9.1	-4.3	-3.2	2.3
Cash from Investing Activities	-231.1	-107.8	-9.3	50.2	-125.9	-42.9	-22.0	-22.8	-0.3	-5.0	-4.2
Purchase of Property, Plant & Equipment	23.0	2.7	1.2	6.4	13.6	5.1	8.2	7.2	0.7	0.9	3.8
Cash from Financing Activities	155.6	43.3	1.7	2.9	107.0	76.1	8.6	35.4	1.7	9.4	0.1
Net Change in Cash	48.7	-11.5	-15.4	35.3	-28.4	34.7	-4.2	3.5	-3.0	1.2	-1.8

Breakdown ₩ bn	2026 Q2	2026 Q1	2025 Q4	2025 Q3	2025 Q2	2025 Q1	2024 Q4	2024 Q3	2024 Q2	2024 Q1
Total Revenue	68.9	71.6	64.5	49.0	18.6	83.7	50.8	4.9	12.2	34.9
Cost of Revenue	7.4	10.1	21.9	9.2	6.6	12.6	17.6	3.0	10.7	7.5
Gross Profit	61.5	61.5	42.6	39.9	12.1	71.1	33.2	1.9	1.5	27.4
Selling, General & Administrative	27.3	22.2	22.9	13.2	12.5	10.1	10.2	10.1	8.3	10.1
Operating Income	34.2	39.3	19.6	26.7	-0.4	61.0	23.0	-8.2	-6.7	17.3
Finance Income	-1.7	35.9	48.6	3.0	2.9	2.0	3.4	1.5	1.7	1.2
Finance Costs	4.0	3.1	4.7	3.2	3.0	1.4	0.3	0.1	0.3	0.0
Pretax Income	32.7	83.7	69.3	30.4	1.1	62.0	28.3	-9.4	-3.2	20.9
Income Tax Expense	2.8	12.3	-5.2	8.3	35.4	-21.0	-24.1	0.0	0.0	0.0
Net Income	30.0	71.3	74.4	22.0	-34.3	83.0	52.4	-9.4	-3.2	20.9
Total Comprehensive Income	30.0	71.3	74.4	22.0	-34.3	83.0	52.4	-9.4	-3.2	20.9

Breakdown ₩ bn	2026 Q2	2026 Q1	2025 Q4	2025 Q3	2025 Q2	2025 Q1	2024 Q4	2024 Q3	2024 Q2	2024 Q1
Total Assets	739.9	729.5	698.7	639.5	602.9	650.3	409.0	299.4	306.3	274.6
Current Assets	521.9	511.5	480.8	441.8	408.1	424.8	211.8	167.4	180.7	157.0
Cash & Cash Equivalents	80.4	42.3	66.4	51.7	63.9	45.1	19.0	27.0	37.8	29.9
Inventories	6.4	6.2	6.5	6.7	2.3	1.6	1.0	0.6	0.3	0.2
Trade Receivables	18.6	41.9	29.6	49.2	14.3	86.0	20.2	4.6	6.8	3.5
Non-current Assets	218.0	218.0	217.9	197.7	194.8	225.5	197.2	132.0	125.6	117.6
Property, Plant & Equipment	55.5	54.4	40.4	26.0	20.7	19.6	19.2	18.8	18.4	18.4
Intangible Assets	116.5	118.3	120.1	119.5	117.8	115.1	112.0	109.2	102.4	96.1
Total Liabilities	192.7	216.6	244.3	261.6	255.2	275.7	134.9	121.9	120.6	105.1
Current Liabilities	188.8	212.4	239.7	256.4	249.5	113.8	129.2	107.6	108.1	97.9
Non-current Liabilities	3.8	4.2	4.6	5.2	5.7	161.9	5.7	14.4	12.5	7.3
Total Equity	547.2	512.9	454.4	377.9	347.7	374.6	274.1	177.5	185.7	169.5
Share Capital	26.8	26.8	26.8	26.8	26.7	26.7	26.7	26.6	26.6	26.5
Retained Earnings	378.7	350.2	218.5	149.3	127.0	160.0	76.9	23.4	32.7	35.6

Breakdown ₩ bn	2026 Q2	2026 Q1	2025 Q4	2025 Q3	2025 Q2	2025 Q1	2024 Q4	2024 Q3	2024 Q2	2024 Q1
Cash from Operating Activities	16.6	21.0	65.0	-4.9	68.8	-4.8	23.1	-0.5	-10.3	40.8
Cash from Investing Activities	40.2	-45.5	-48.7	-10.4	-49.6	-122.4	-40.2	-10.1	-11.3	-46.1
Purchase of Property, Plant & Equipment	2.4	13.9	14.9	5.7	1.5	0.9	1.1	1.0	0.5	0.1
Cash from Financing Activities	-18.2	-0.1	-0.1	2.5	-0.2	153.4	8.9	-0.1	29.6	4.9
Net Change in Cash	38.5	-24.6	16.2	-12.8	19.1	26.2	-8.3	-10.7	7.9	-0.4

Consolidated (CFS), from DART. 11 fiscal years and 10 quarters. Accounts matched on IFRS account_id, not Korean labels, so the same line holds across years where the Korean wording changed. Quarterly figures are three-month values: income quarters from DART's three-month column, cash-flow quarters differenced from DART's cumulative figures, and Q4 as annual minus nine-month cumulative.

196170 Growth

FY2025 ₩bn	Latest	1-yr	3-yr CAGR	5-yr CAGR	10-yr CAGR
Revenue	215.9	+109.9%	+95.7%	+38.5%	+46.5%
Operating income	106.9	+320.8%	—	—	+96.6%
Net income	145.2	+139.2%	—	—	+61.4%
EPS	₩2,084	+139.2%	—	—	+61.4%
Operating cash flow	124.1	+134.0%	—	+141.5%	+49.2%
Shareholders' equity	454.4	+65.8%	+46.2%	+49.6%	+28.0%

Compound annual growth from the DART annual statements on this page. n/m where either end of the period is a loss or missing. EPS uses today's share count for every year.

196170 Profitability

Ratio	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020
Gross margin	76.7%	62.3%	32.3%	15.7%	14.9%	44.2%
Operating margin	49.5%	24.7%	-10.1%	-102.0%	-39.2%	-0.1%
Net margin	67.3%	59.0%	-3.7%	-35.0%	-29.9%	-43.1%
Return on equity	39.9%	28.8%	-2.4%	-7.3%	-12.1%	-27.9%
Return on assets	26.2%	18.2%	-1.4%	-4.0%	-5.6%	-14.9%
Operating cash flow / revenue	57.5%	51.6%	-8.0%	-62.1%	-24.4%	3.6%
Capex / revenue	10.7%	2.6%	1.3%	22.3%	35.1%	12.1%

Margins divide by revenue for the same year. Return on equity and assets divide net income by the average of that year's and the prior year's balance, as DART reports them (consolidated, including minority interests).

Similar to 196170

Symbol	Last Price
207940Samsung Biologics Co., Ltd.	₩1,447,000 -2.0%
068270Celltrion, Inc.	₩188,100 +0.5%
326030SK biopharmaceuticals Co., Ltd.	₩86,600 +0.2%
128940Hanmi Pharm. Co., Ltd.	₩473,500 +2.8%
000100Yuhan Corporation	₩81,400 +0.0%
028300HLB Co., Ltd.	₩33,750 +2.9%
298380ABL Bio Inc.	₩71,400 +5.6%
000250Samchundang Pharm	₩157,000 +1.0%
087010Peptron, Inc.	₩157,300 +7.3%
141080LigaChem Biosciences Inc.	₩92,000 +4.2%

Compare all 48 in Biopharma

What a US investor should know

Trading hours09:00–15:30 KST — 20:00–02:30 US Eastern the night before.
Daily limitKorean stocks can move at most ±30% in a session before trading halts.
Getting exposureKRX shares are not directly tradable in most US brokerage accounts. The usual routes are Korea ETFs or an international account.
ReportingKorean issuers file to DART, not the SEC. Half-year and quarterly reports land about 45 days after period end.